Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

NCT06702826 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Brain Metastases
Stereotactic Radiation
Immunotherapy

Interventions

DRUG: Cadonilimab combined with SRS

Sponsor

Rongrong Zhou